银屑病或银屑病关节炎患者接受生物制剂治疗时COVID-19风险与结局:已发表证据质量的批判性评估
该研究评估了银屑病或银屑病关节炎患者接受生物制剂治疗时COVID-19风险与结局相关论文的方法学质量。共纳入25篇论文,纽卡斯尔-渥太华量表评分中位数银屑病为47%、银屑病关节炎为44%,提示总体偏倚风险高。所有论文均存在显著偏倚风险,未来研究需减少 ascertainment 偏倚、考虑无应答或参与偏倚并进行正式统计效能计算。
要点
- 已发表文献方法学质量普遍偏低,偏倚风险高。
- 部分研究将疑似COVID-19但未获阳性拭子者纳入分析。
- 无研究提供正式的样本量计算。
核心结论
- 已发表的关于银屑病或银屑病关节炎患者接受生物制剂治疗时COVID-19风险与结局的论文均存在显著偏倚风险。
研究设计与样本
- 对141篇论文进行筛选,最终纳入25篇进行质量评估。
- 使用纽卡斯尔-渥太华量表评估研究质量,并额外考虑病例定义、COVID-19评估方式、自选择证据、脱落/未参与百分比及样本量计算等内部和外部有效性条目。
主要发现
- 纽卡斯尔-渥太华量表评分中位数银屑病为47%,银屑病关节炎为44%,表明总体偏倚风险高。
- 37%的银屑病研究和44%的银屑病关节炎研究纳入了疑似COVID-19但无阳性拭子的患者。
- 没有研究提供正式的样本量计算。
临床怎么用
- 临床解读相关文献时需警惕高偏倚风险,谨慎对待其结论。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The need to rapidly spread information about the risk of COVID-19 in patients with psoriasis and psoriatic arthritis on biologics may have hampered the methodological rigor in published literature. We analyzed the quality of papers dealing with the risk and outcomes of COVID-19 in patients with psoriasis and psoriatic arthritis receiving biologic therapies. The Newcastle-Ottawa Scale was used to estimate the quality of the published studies. Moreover, to better contextualize results, specific internal and external validity items were further considered, that is, case definition, modality of COVID-19 assessment, evidence for self-selection of participants, percentage of dropout/nonparticipants, and sample size calculation. A total of 25 of 141 papers were selected. The median Newcastle-Ottawa Scale score was 47% for psoriasis and 44% for psoriatic arthritis, indicating an overall high risk of bias. A total of 37% of psoriasis and 44% of psoriatic arthritis studies included patients with suspected COVID-19 without a positive swab. No studies provided a formal sample size calculation. A significant risk of bias in all the published papers was found. Major issues to be considered in future studies are reduction of ascertainment bias, better consideration of nonresponse or participation bias, and provision of formal statistical power calculation.
引用
- Piaserico S, Gisondi P, Cazzaniga S, et al. Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. J Invest Dermatol. 2021. PMID: 34363826. doi:10.1016/j.jid.2021.04.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。